Hemophilia A Treatment Factors and Outcomes

EP: 1.Management Insights for Patients With Hemophilia

EP: 2.Coverage Decisions for Expensive Hemophilia Treatments

EP: 3.Impact of ICER Reports on Hemophilia Treatment Decisions

EP: 4.Enhancing Provider Access and Expertise for Rare Disease Care

EP: 5.Factors Impacting Hemophilia A Care Costs

EP: 6.Collaborative Strategies in Hemophilia A Care Cost Management

EP: 7.Strategies to Manage Medication Costs and Waste

EP: 8.Adapting to Novel Hemophilia A Treatments

EP: 9.Comprehensive Insights into Hemophilia A: Prevalence, Clinical Impact, and Economic Considerations

EP: 10.Evolution of the Hemophilia A Treatment Landscape: Innovations and Guidelines

Now Viewing

EP: 11.Hemophilia A Treatment Factors and Outcomes

EP: 12.Prophylactic Treatment Challenges and Considerations for Hemophilia A

EP: 13.Consequences of Nonadherence in Hemophilia A

EP: 14.Advancements in Hemophilia A Therapies

EP: 15.Comparing Hemophilia A Therapies: Efficacy and Safety Insights

EP: 16.Real-World Insights: Factor vs Emicizumab in Hemophilia A

EP: 17.Emicizumab Dosing: Prophylaxis and Bleeding Management

EP: 18.Optimizing Hemophilia Treatment: Strategies and Adherence

EP: 19.Advancements in Hemophilia A Therapies: Altuviiio and Roctavian

EP: 20.Advancements in Hemophilia A Treatment: Fitusiran and the Evolving Landscape

This is a video synopsis/summary of an Insights involving Allison Wheeler, MD.

Wheeler delves into the multifaceted considerations when determining the appropriate treatment for hemophilia A, emphasizing the importance of patient-specific factors. She starts with evaluating baseline factor activity and disease severity, underlining the need to adapt treatment to individual needs. Early prophylactic therapy initiation, historically around 1 year of life, has been a standard for severe disease. The evolving landscape now includes nonfactor products, allowing for more flexibility in administration, catering to patient preferences.

Addressing prophylactic versus on-demand therapy for severe hemophilia A, Wheeler unequivocally advocates for prophylaxis, referencing Marilyn Manco-Johnson’s influential work showing improved joint outcomes. The standard of care involves initiating prophylactic treatment early, with advancements like factor VIII mimetic enabling earlier intervention. Wheeler emphasizes the reduction in bleeding episodes and joint damage, and improvement in quality of life with prophylaxis. Acknowledging the impact of untreated patients experiencing daily pain and restricted joint movement, she asserts prophylactic treatment as a crucial element for enhancing patient outcomes, making it a standard of care for severe hemophilia A.

Video synopsis is AI-generated and reviewed by AJMC^® editorial staff.